Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Empagliflozin in acute myocardial infarction: the EMMY trial

Open access

Abstract

Aims: Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. Methods and results: In this academic, multicentre, double-blind trial, patients (n = 476) with acute myocardial infarction accompanied by a large creatine kinase elevation (>800 IU/L) were randomly assigned to empagliflozin 10 mg or matching placebo once daily within 72 h of percutaneous coronary intervention. The primary outcome was the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks. Secondary outcomes included changes in echocardiographic parameters. Baseline median (interquartile range) NT-proBNP was 1294 (757–2246) pg/mL. NT-proBNP reduction was significantly greater in the empagliflozin group, compared with placebo, being 15% lower [95% confidence interval (CI) −4.4% to −23.6%] after adjusting for baseline NT-proBNP, sex, and diabetes status (P = 0.026). Absolute left-ventricular ejection fraction improvement was significantly greater (1.5%, 95% CI 0.2–2.9%, P = 0.029), mean E/e′ reduction was 6.8% (95% CI 1.3–11.3%, P = 0.015) greater, and left-ventricular end-systolic and end-diastolic volumes were lower by 7.5 mL (95% CI 3.4–11.5 mL, P = 0.0003) and 9.7 mL (95% CI 3.7–15.7 mL, P = 0.0015), respectively, in the empagliflozin group, compared with placebo. Seven patients were hospitalized for heart failure (three in the empagliflozin group). Other predefined serious adverse events were rare and did not differ significantly between groups. Conclusion: In patients with a recent myocardial infarction, empagliflozin was associated with a significantly greater NT-proBNP reduction over 26 weeks, accompanied by a significant improvement in echocardiographic functional and structural parameters. ClinicalTrials.gov registration: NCT03087773.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac494

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Structured graphical abstract A total of 476 people with acute myocardial infarction were randomized to either empagliflozin 10 mg or matching placebo once daily within 72 h of acute percutaneous coronary intervention. The change in NT-proBNP concentrations as well as echocardiographic functional and structural parameters over 26 weeks of treatment was evaluated. LVEF, left-ventricular ejection fraction; LVEDV, left-ventricular end-diastolic volume; LVESV, left-ventricular end-systolic volume; NT-proBNP, N-terminal pro-hormone of brain natriuretic peptide.
Structured graphical abstract A total of 476 people with acute myocardial infarction were randomized to either empagliflozin 10 mg or matching placebo once daily within 72 h of acute percutaneous coronary intervention. The change in NT-proBNP concentrations as well as echocardiographic functional and structural parameters over 26 weeks of treatment was evaluated. LVEF, left-ventricular ejection fraction; LVEDV, left-ventricular end-diastolic volume; LVESV, left-ventricular end-systolic volume; NT-proBNP, N-terminal pro-hormone of brain natriuretic peptide.CC BY-NC · PubMed Central
Figure 1 Patient disposition. *Baseline N-terminal pro-hormone of brain natriuretic peptide and at least one follow-up N-terminal pro-hormone of brain natriuretic peptide measurement at the central laboratory were available.
Figure 1 Patient disposition. *Baseline N-terminal pro-hormone of brain natriuretic peptide and at least one follow-up N-terminal pro-hormone of brain natriuretic peptide measurement at the central laboratory were available.CC BY-NC · PubMed Central
Figure 2 (A) Percentage decline across all visits in N-terminal pro-hormone of brain natriuretic peptide concentration by treatment group (log-transformed data). (B) Percentage decline at Week 26 as function of N-terminal pro-hormone of brain natriuretic peptide at baseline (empagliflozin group). (C) Percentage decline at Week 26 as function of N-terminal pro-hormone of brain natriuretic peptide at baseline (placebo group).
Figure 2 (A) Percentage decline across all visits in N-terminal pro-hormone of brain natriuretic peptide concentration by treatment group (log-transformed data). (B) Percentage decline at Week 26 as function of N-terminal pro-hormone of brain natriuretic peptide at baseline (empagliflozin group). (C) Percentage decline at Week 26 as function of N-terminal pro-hormone of brain natriuretic peptide at baseline (placebo group).CC BY-NC · PubMed Central
Figure 3 Changes in echocardiographic parameters by treatment group: (A) left-ventricular ejection fraction, (B) E/e′, (C) left-ventricular end-systolic volume, and (D) left-ventricular end-diastolic volume.
Figure 3 Changes in echocardiographic parameters by treatment group: (A) left-ventricular ejection fraction, (B) E/e′, (C) left-ventricular end-systolic volume, and (D) left-ventricular end-diastolic volume.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 303

Metadata

Authors
von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., Moertl, D., Auersperg, P., Reiter, C., Rieder, T., Siller-Matula, J. M., Gager, G. M., Hasun, M., Weidinger, F., Pieber, T. R., Zechner, P. M., Herrmann, M., Zirlik, A., Holman, R. R., Oulhaj, A., & Sourij, H.
Affiliations
  • Department of Internal Medicine, Division of Cardiology, Medical University of Graz , Auenbruggerplatz 15, 8036 Graz , Austria
  • Medical University of Graz (AT)
  • Klinikum Klagenfurt (AT)
  • Department of Internal Medicine, Brothers of Saint John of God Eisenstadt , Eisenstadt , Austria
  • Paracelsus Medical University (AT)
  • Vorarlberg Institute for Vascular Investigation and Treatment (AT)
  • Universitätsklinikum St. Pölten (AT)
  • Kepler Universitätsklinikum (AT)
  • Department of Medicine, Kardinal Schwarzenberg Hospital Schwarzach , Schwarzach , Austria
  • Medical University of Vienna (AT)
  • 2nd Medical Department with Cardiology and Intensive Care Medicine, Hospital Landstrasse , Vienna , Austria
  • Department of Cardiology and Intensive Care Medicine, Hospital Graz South West, West Location , Graz , Austria
  • University of Oxford (GB)
  • Khalifa University of Science and Technology (AE)
Corresponding author
Sourij, Harald
Venue
European Heart Journal
Published
2022-08-29
Volume
43
Issue
41
Pages
4421-4432
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4293447102
Cited by
303
References
51
Citations by year
2026: 46 · 2025: 68 · 2024: 104 · 2023: 74 · 2022: 10
FWCI
47.45
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Boehringer Ingelheim (1245.151)
  • Roche Diagnostics Austria
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
empagliflozin, acute myocardial infarction, SGLT2 inhibitors, NT-proBNP, left ventricular ejection fraction, left ventricular remodeling, heart failure, percutaneous coronary intervention, creatine kinase elevation, echocardiographic parameters, myocardial stunning, myocardial stunning recovery, myocardial stunning duration
MeSH terms
Benzhydryl Compounds, Glucosides, Heart Failure, Humans, Myocardial Infarction, Peptide Fragments, Stroke Volume, Biomarkers, Ventricular Function, Left, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empagliflozin in acute myocardial infarction: the EMMY trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehac494
The paper
von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., Moertl, D., Auersperg, P., Reiter, C., Rieder, T., Siller-Matula, J. M., Gager, G. M., Hasun, M., Weidinger, F., Pieber, T. R., . . . Sourij, H. (2022). Empagliflozin in acute myocardial infarction: the EMMY trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac494

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.